




PHARMACEUTICAL 2021

Apellis Pharmaceuticals Inc.
Rank 291 of 402





PHARMACEUTICAL 2021

Apellis Pharmaceuticals Inc.
Rank 291 of 402



The relative strengths and weaknesses of Apellis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Apellis Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Apellis Pharmaceuticals Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.81%, being 47% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	917,192
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	128,327
Liabilities, Non-Current	15,217
Other Assets	36,574
Other Compr. Net Income	37
Other Expenses	56,832
Other Liabilities	612,468
Other Net Income	-99,366
Other Revenues	250,646
Property and Equipment	6,803
Research and Development	299,921
Selling, General and Administrative Expense	139,401

Output Variable	Value in 1000 USD
Assets	960,569
Liabilities	756,012
Expenses	496,154
Revenues	250,646
Stockholders Equity	204,557
Net Income	-344,874
Comprehensive Net Income	-344,856
Economic Capital Ratio	0.81%